Avid is responsible for the manufacturing part of the IND application.

Avid Bioservices will manufacture clinical-grade material for Catalyst Biosciences to support development of its version of factor VIIa for the treatment of acute bleeding in hemophilia patients. CB 813 is currently in preclinical development.

Avid Bioservices will begin manufacturing drug supply under cGMP regulations and provide cell-bank preparation, process development, and preparation of the manufacturing portion of the IND application.

“Avid’s expertise in the scale-up and manufacture of clinical-grade biotechnology therapeutics and their strong customer orientation made them a good choice for Catalyst,” explains Nassim Usman, Ph.D., CEO of Catalyst Biosciences.

Previous articleWnt Pathway Key to Blood-Brain Barrier Formation
Next articleRaynard S. Kington to Serve as NIH Acting Director